Vetanic develops various regenerative medicine products, including canine iPS cell-derived mesenchymal stem cells (MSCs). Regenerative medicine, which is being put to practical use in humans, is expected to spread to veterinary medicine too. However, at present, this has been applied only at a small number of veterinary clinics meeting the facility requirements due to issues such as inconsistent quality, treatment lead time, and the high cost of treatment. The company has succeeded in producing the world's only canine iPS cells suitable for clinical application. It will promote the development of MSCs, which are currently in high demand in veterinary medicine. Furthermore, it plans to gradually develop various regenerative medicine products other than MSCs, taking advantage of the high-quality, low-cost, donor-free, and ethical characteristics of iPS cell-derived products.